Barberi-Heyob M, Watelet M, Merlin J L, Bleger C, Schroeder B
Laboratoire de recherche en oncologie, France.
Bull Cancer. 1995 Dec;82(12):1025-31.
To follow therapeutic evolutions and to ensure an international homogeneity, "Produits Roche" Laboratories recently modified the conditioning of 5-fluorouracil (5-FU): the Tris buffer was replaced by sodium hydroxide (pH 9.4). For these newly-formulated 5-FU solutions, we studied the optimal conditions of storage according to concentration (0.2; 1.5 and 10 mg/ml), temperature (4, 21 and 37 degrees C), light (without, natural, artificial) and duration (7, 15 and 30 days) for plastic bags, syringes and cassettes. 5-FU was dosaged by High Performance Liquid Chromatography (HPLC). No staining was observed, but for the samples placed at 4 degrees C, we detected macroscopically the apparition of crystals, more or less rapidly according to 5-FU concentration. For plastic bags at 0.2 mg/ml of 5-FU in NaCl (0.9%), 48 hours were sufficient for crystallisation. For preparations at 10 and 50 mg/ml, the formation of crystals occurred in less than 24 hours. However, no microscopic analysis was performed and therefore, in shorter delays, the formation of microcrystals can be envisaged. After 7 days, only the storage in darkness at 21 degrees C yields good results of stability for cassettes and syringes at 50 mg/ml with a degradation of the active component that does not exceed 2%. However, in the same optimal conditions, a storage superior to 14 days cannot be envisaged since we noted a 10% diminution of the active component, then this loss intensifies and reaches 18% after 30 days of storage. For plastic bags at 0.2 and 1.5 mg/ml of 5-FU, we did not measure any significant difference between the various storage conditions, even during 14 days. At 10 mg/ml concentration, a storage during 7 days in darkness can be envisaged with no repercussion on the 5-FU stability. Independently of concentration, special attention must be paid to the risk of crystallisation at 4 degrees C.
为跟踪治疗进展并确保国际同质性,“罗氏产品”实验室最近对5-氟尿嘧啶(5-FU)的包装进行了修改:用氢氧化钠(pH 9.4)取代了Tris缓冲液。对于这些新配制的5-FU溶液,我们根据浓度(0.2;1.5和10mg/ml)、温度(4、21和37摄氏度)、光照(无、自然、人工)和持续时间(7、15和30天),研究了塑料袋、注射器和药盒的最佳储存条件。5-FU通过高效液相色谱法(HPLC)进行定量。未观察到染色现象,但对于置于4摄氏度的样品,我们肉眼检测到晶体的出现,根据5-FU浓度不同,出现速度或多或少有所不同。对于在NaCl(0.9%)中含0.2mg/ml 5-FU的塑料袋,48小时足以结晶。对于10和50mg/ml的制剂,晶体形成在不到24小时内发生。然而,未进行显微镜分析,因此,在更短的时间内,可能会形成微晶。7天后,对于50mg/ml的药盒和注射器,只有在21摄氏度黑暗条件下储存才能获得良好的稳定性结果,活性成分降解不超过2%。然而,在相同的最佳条件下,不能设想储存超过14天,因为我们注意到活性成分减少了10%,然后这种损失加剧,储存30天后达到18%。对于含0.2和1.5mg/ml 5-FU的塑料袋,即使在14天内,我们也未在各种储存条件之间测量到任何显著差异。在10mg/ml浓度下,可以设想在黑暗中储存7天,而不会对5-FU稳定性产生影响。无论浓度如何,都必须特别注意4摄氏度时结晶的风险。